Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 9/20 | 0.48 |
| ▸ | MTOR | P42345 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284158 | 0.88 | PIK3CA (0.55) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD | |
| SCHEMBL1284571 | 0.88 | PIK3CA (0.49) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD | |
| SCHEMBL1284054 | 0.86 | PIK3CA (0.47) | PIK3CAPIK3R1MTORALDH1A1SMN1; SMN2 | |
| SCHEMBL1180613 | 0.85 | PIK3CA (0.47) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD | |
| SCHEMBL1857391 | 0.83 | PIK3CA (0.48) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL4438977 | 0.83 | PIK3CA (0.45) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD | |
| SCHEMBL2817644 | 0.83 | PIK3CA (0.51) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD | |
| SCHEMBL189807 | 0.83 | PIK3CA (0.53) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD | |
| SCHEMBL1088049 | 0.83 | PIK3CA (0.58) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL1285138 | 0.83 | PIK3CA (0.48) | PIK3CAPIK3R1MTORSMN1; SMN2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-16 | — | — | US | disclosed |
| US-8802670-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3R1 15/4885MTOR 37/4885 |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | PIK3CA 1/4885PIK3R1 19/4885MTOR 17/4885 |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | PIK3CA 1/4885PIK3R1 19/4885MTOR 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.